September 28, 2016 2:02 AM ET

Pharmaceuticals

Company Overview of Arbor Pharmaceuticals, LLC

Company Overview

Arbor Pharmaceuticals, LLC, a specialty pharmaceutical company, researches, develops, manufactures, and commercializes prescription products for cardiovascular, hospital, neuroscience, and pediatric markets. The company develops new chemical entities, as well as already approved molecules for new indications or in improved dosage forms. It offers nitroglycerin lingual sprays for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease; angiotensin II receptor blockers that help blood vessels relax so that blood flows through them freely; and isosorbide dinitrate/hydralazine HCL for the treatment of heart failure. The company also provides carmustine implants...

Six Concourse Parkway

Suite 1800

Atlanta, GA 30328

United States

Founded in 2006

Phone:

678-334-2420

Fax:

470-235-2403

Key Executives for Arbor Pharmaceuticals, LLC

Chief Executive Officer, President and Director
Age: 64
Chief Financial Officer
Chief Compliance Officer, Vice President and General Counsel
Age: 47
Head of Business Development
Vice President of Commercial Operations
Age: 49
Compensation as of Fiscal Year 2016.

Arbor Pharmaceuticals, LLC Key Developments

Laboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC Announce the Launch of OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) Otic Solution

Laboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC jointly announce the launch of OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) otic solution, the first and only antibiotic and steroid combination ear drop available in sterile, preservative-free single-dose vials. OTOVEL® is owned by SALVAT, and Arbor will be the exclusive distributor of the product in the U.S. OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) is indicated for the treatment of acute otitis media with tympanostomy tubes (AOMT) in pediatric patients (aged 6 months and older) due to S. aureus, S. pneumoniae, H. influenzae, M. catarrhalis, and P. aeruginosa. Two phase 3 multicenter, randomized, double-blind, active-controlled, parallel group trials were conducted to assess the efficacy and safety of OTOVEL® compared to ciprofloxacin otic solution and to fluocinolone acetonide otic solution.

Arbor Pharmaceuticals, LLC Launches Cetylev

Arbor Pharmaceuticals, LLC announced the launch of Cetylev (acetylcysteine) effervescent tablets for oral solution, a new acetaminophen overdose antidote with a lemon-mint taste and smell. Cetylev prevents and reduces injury to the liver after acute and chronic toxic acetaminophen ingestion. The effervescent tablets are simply dropped into water which dissolve into a pleasant lemon-mint flavored and scented oral solution. Currently, acetylcysteine solution is available in vials intended for inhalation which pharmacists typically mix with a diet cola for ingestion orally; a practice intended to mask the reported “rotten-egg” smell and taste. Another acetylcysteine treatment comes in an intravenous formulation. Cetylev is now commercially available to hospitals and being promoted by Arbor’s national Hospital Specialty Sales Team.

Debiopharm International SA and Arbor Pharmaceuticals, LCC Announce Execution of Distribution Agreement

Debiopharm International SA and Arbor Pharmaceuticals, LCC jointly announced the execution of a distribution agreement for the commercialization and promotion of triptorelin 22.5 mg in the United States for central precocious puberty (CPP). Under the terms of the agreement, Arbor acquires exclusive commercial rights for triptorelin 22.5 mg in the U.S., for the CPP indication. The product will be exported from Debiopharm Research and Manufacturing SA to Arbor. Once approved, triptorelin 22.5 mg will be made available primarily to pediatricians and pediatric endocrinologists.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
May 23, 2016
Xenoport, Inc.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Arbor Pharmaceuticals, LLC, please visit www.arborpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.